Statements (89)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
gptkb:CureVac's_mRNA_platform
|
| gptkbp:CEO |
Bassil_Dahiyat
|
| gptkbp:clinicalTrials |
gptkb:XmAb18093
gptkb:XmAb18089 gptkb:XmAb18072 gptkb:XmAb18079 gptkb:XmAb18087 gptkb:XmAb18050 gptkb:XmAb18100 gptkb:Xencor_357 gptkb:XmAb18060 gptkb:XmAb18098 gptkb:XmAb18052 gptkb:XmAb18092 gptkb:XmAb18083 gptkb:XmAb18049 gptkb:XmAb20717 gptkb:XmAb18064 gptkb:XmAb18073 gptkb:XmAb18078 gptkb:XmAb18080 gptkb:XmAb18074 multiple drug candidates biopharmaceutical company XmAb14045 XmAb14047 XmAb18048 XmAb18051 XmAb18053 XmAb18054 XmAb18055 XmAb18056 XmAb18057 XmAb18058 XmAb18059 XmAb18061 XmAb18062 XmAb18063 XmAb18065 XmAb18066 XmAb18067 XmAb18068 XmAb18069 XmAb18070 XmAb18071 XmAb18075 XmAb18076 XmAb18077 XmAb18081 XmAb18082 XmAb18084 XmAb18085 XmAb18086 XmAb18088 XmAb18090 XmAb18091 XmAb18094 XmAb18095 XmAb18096 XmAb18097 XmAb18099 XmAb22841 XmAb24306 XmAb7195 XmAb13676 |
| gptkbp:collaborations |
gptkb:Pfizer
|
| gptkbp:employees |
over 200
|
| gptkbp:focus |
cancer therapies
therapeutics for autoimmune diseases |
| gptkbp:founded |
2004
|
| gptkbp:founder |
Bassil_Dahiyat
|
| gptkbp:headquarters |
gptkb:Monrovia,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Xencor
|
| gptkbp:partnerships |
gptkb:Bristol-Myers_Squibb
gptkb:Amgen Novartis Sanofi |
| gptkbp:research_areas |
oncology
immunology |
| gptkbp:research_focus |
protein engineering
|
| gptkbp:revenue |
$100 million (2022)
|
| gptkbp:sells |
XNCR
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:technology |
antibody-drug conjugates
Fc engineering XmAb technology platform |
| gptkbp:tributaryOf |
monoclonal antibodies
bispecific antibodies |